WST|Analyst Targets
WST|Company Info
WST|Insider Trading
WST|Fundamentals
WST|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.20 | - | - |
| Q1'26 | $2.05 | $2.13 | +3.8% |
| Q4'25 | $1.67 | $2.04 | +22.1% |
| Q3'25 | $1.71 | $1.96 | +14.6% |
| Q2'25 | $1.54 | $1.84 | +19.7% |
| Q1'25 | $1.26 | $1.45 | +15.3% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $827M | - | - |
| Q1'26 | $835M | $845M | +1.2% |
| Q4'25 | $773M | $805M | +4.1% |
| Q3'25 | - | $805M | - |
| Q2'25 | - | $767M | - |
| Q1'25 | - | $698M | - |
WST|Monthly Returns
Market Data
WST Stock Snapshot
- Market cap
- 27.19B
- P/E ratio
- 48.1
- Day range
- $372.21 – $379.21
- News sentiment
- 45/100 · Neutral
- Analyst target
- $412.88 (+9.8%)
- Consensus
- Buy · 25 analysts
WST is trading with the trend behind it, which is what pushes the technical read bullish. In Healthcare, names this size usually take direction from sector flows before company-level news.
Reverse DCF
What growth is priced into WST?
At today's price, West Pharmaceutical Services, Inc. needs to grow free cash flow about 33.8% a year for the next 10 years to justify its valuation at a 8.81% cost of capital. Over its actual history it has compounded free cash flow at 18.8% a year, so the market is asking for 15.0 percentage points above its own delivered rate. On that basis WST looks priced above what its own growth record supports.
- Implied FCF growth
- 33.8%
- Historical FCF CAGR
- 18.8%
- Growth gap
- +15.0 pts
- Verdict
- RICH
- Discount rate (WACC)
- 8.81%
- Beta
- 0.72
Behaviour On Record
What WST's own history says about today's numbers
- Realized volatility (21d)
- 23.0% 44th pct
- Below its peak
- -21.1%
- vs 200-day average
- +21.8%
- Up days (1y)
- 53%
West Pharmaceutical Services, Inc. is currently running 23.0% annualised volatility over the last 21 sessions. Measured against WST's own 13 years of daily returns rather than a market-wide average, that is the 44th percentile — close to its own typical level, against a typical reading of 24.4%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
WST is trading -21.1% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -22.9%, and the deepest was -53.0% in 2022. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits +21.8% from its 200-day moving average. Against every other day in its history, that gap ranks at the 85th percentile — a wider gap than this stock usually carries. Over the past year WST closed higher on 53% of sessions, and it is currently 3 sessions into a rising streak.
On October specifically: over 13 years of records, WST finished the month higher 9 of 13 times, with a median return of +2.7% and an average of +1.3%. Its strongest month historically has been June at +4.6% on average, its weakest February at -2.1%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: WST has opened more than 2% away from the prior close in 91 of 3,267 sessions (2.8% of the time), with the largest gaps running +9.1% and -15.7%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against WST's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of WST's sector?
West Pharmaceutical Services, Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).
- Sector rank
- #2 of 12
- Sector state
- Leading
- Sector rotation score
- 91
Analyst Rating Changes
Are analysts turning bullish or bearish on WST?
TD Cowen most recently reiterated its rating on West Pharmaceutical Services, Inc. to Buy on Oct 13, 2026 with a price target of $420 (from $410). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.
- Latest action
- TD Cowen — Buy
- 90-day upgrades
- 1
- 90-day downgrades
- 0
- Net rating momentum
- +1
Peers & ETF holders
WST peers & ETF holders
Medical Instruments & SuppliesMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▼ Sell | 9,539,173 | 13.05% | $2.62B | 2026-01-29 |
| BlackRock, Inc. | ▼ Sell | 6,651,784 | 9.10% | $2.39B | 2026-08-07 |
| FMR LLC (Fidelity) | ▲ Buy | 3,574,816 | 4.89% | $1.28B | 2026-08-13 |
| Artisan Partners Limited Partnership | ▼ Sell | 2,411,792 | 3.30% | $865.83M | 2026-08-13 |
| Geode Capital Management, LLC | ▼ Sell | 1,903,279 | 2.60% | $680.55M | 2026-08-12 |
| Morgan Stanley | ▲ Buy | 1,582,546 | 2.16% | $568.14M | 2026-08-13 |
| JPMorgan Chase & Co | ▲ Buy | 1,164,527 | 1.59% | $413.03M | 2026-08-12 |
| Invesco Ltd. | ▼ Sell | 1,009,852 | 1.38% | $362.54M | 2026-08-14 |
| Norges Bank | ▼ Sell | 862,915 | 1.18% | $309.79M | 2026-08-12 |
| Goldman Sachs Group Inc | ▲ Buy | 814,772 | 1.11% | $292.50M | 2026-08-14 |
| Northern Trust Corp | ▼ Sell | 709,421 | 0.97% | $254.68M | 2026-08-13 |
| Capital Research Global Investors | ▲ Buy | 609,221 | 0.83% | $218.71M | 2026-08-12 |
| William Blair Investment Management, LLC | ▲ Buy | 417,309 | 0.57% | $149.81M | 2026-08-12 |
| Citadel Advisors LLC | ▲ Buy | 352,769 | 0.48% | $126.64M | 2026-09-02 |
| Bank of America Corp | ▼ Sell | 350,482 | 0.48% | $125.82M | 2026-08-14 |
| Point72 Asset Management, L.P. | ▲ Buy | 283,396 | 0.39% | $101.74M | 2026-08-14 |
| Citigroup Inc | ▲ Buy | 190,778 | 0.26% | $68.49M | 2026-08-03 |
| Wellington Management Group LLP | ▼ Sell | 175,052 | 0.24% | $62.84M | 2026-08-14 |
| Prudential Financial Inc | ▲ Buy | 143,328 | 0.20% | $51.45M | 2026-08-12 |
| Wells Fargo & Company | ▲ Buy | 114,107 | 0.16% | $40.96M | 2026-08-14 |
| Marshall Wace, LLP | ▲ Buy | 83,578 | 0.11% | $30.00M | 2026-08-13 |
| Adage Capital Partners GP, L.L.C. | ▼ Sell | 59,007 | 0.08% | $21.18M | 2026-08-14 |
| AQR Capital Management LLC | ▼ Sell | 57,609 | 0.08% | $20.33M | 2026-08-14 |
| AllianceBernstein L.P. | ▼ Sell | 76,356 | 0.10% | $19.14M | 2026-08-14 |
| Balyasny Asset Management L.P. | ▲ Buy | 45,766 | 0.06% | $16.43M | 2026-08-14 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-07-22 | 2025-08-13 |
| Lisa McClain | House | MI09 | ▲ Buy | $1K - $15K | 2025-06-17 | 2025-08-13 |
| Rob Bresnahan | House | PA08 | ▼ Sell | $1K - $15K | 2025-04-08 | 2025-05-08 |
| Rob Bresnahan | House | PA08 | ▲ Buy | $1K - $15K | 2025-02-25 | 2025-03-27 |
| Jared Moskowitz | House | FL23 | ▼ Sell | $1K - $15K | 2025-02-13 | 2025-03-06 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $1K - $15K | 2022-03-30 | 2022-04-08 |
| Tommy Tuberville | Senate | AL | ▲ Buy | $1K - $15K | 2021-03-29 | 2021-07-23 |
| Thom Tillis | Senate | NC | ▼ Sell | $1K - $15K | 2015-02-13 | 2015-02-26 |